SCHEMBL18990152

SCHEMBL18990152

Cn1c(NCCO)nc2c1c(=O)n(Cc1ccc(Cl)c(Cl)c1)c(=O)n2C

nearest known ligand 0.80

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 8/20 0.80
▸ TP53 P04637 5/20 0.80
▸ USP2 O75604 1/20 0.71
▸ TSHR P16473 1/20 0.71
▸ HIF1A Q16665 2/20 0.69
▸ ALDH1A1 P00352 2/20 0.68
▸ PKM P14618 2/20 0.68
▸ HPGD P15428 1/20 0.68
▸ NPSR1 Q6W5P4 1/20 0.68
▸ MTHFD2 P13995 1/20 0.67
▸ POLB P06746 2/20 0.60
▸ THRB P10828 1/20 0.60
▸ PCSK9 Q8NBP7 1/20 0.58
▸ SMN1; SMN2 Q16637 2/20 0.58
▸ LMNA P02545 1/20 0.58
▸ STAT6 P42226 1/20 0.58
▸ GAA P10253 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18990025 0.93 MAPT (0.82) MAPTTP53USP2TSHRHIF1A
SCHEMBL18989811 0.91 MAPT (0.72) MAPTTP53USP2TSHRHIF1A
SCHEMBL18989786 0.89 MAPT (0.76) MAPTTP53USP2TSHRHIF1A
SCHEMBL18990017 0.88 MAPT (0.75) MAPTTP53USP2TSHRHIF1A
SCHEMBL18990039 0.88 MAPT (0.75) MAPTTP53USP2TSHRHIF1A
SCHEMBL18990826 0.88 MAPT (0.77) MAPTTP53USP2TSHRHIF1A
SCHEMBL20592277 0.88 POLB (0.78) MAPTTP53USP2TSHRHIF1A
SCHEMBL18989932 0.88 MAPT (0.74) MAPTTP53USP2TSHRHIF1A
SCHEMBL18990094 0.87 MAPT (0.76) MAPTTP53USP2TSHRHIF1A
SCHEMBL18990012 0.87 MAPT (0.76) MAPTTP53USP2TSHRHIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12187728-B2 Caffeine inhibitors of MTHFD2 and uses thereof RAZE THERAPEUTICS, INC. (US) 2025-01-07 — — US disclosed
US-20230067237-A1 CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF RAZE THERAPEUTICS, INC. 2023-03-02 — — US disclosed
US-20230067237-A1 CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF RAZE THERAPEUTICS, INC. 2023-03-02 — — US disclosed
US-11370792-B2 Caffeine inhibitors of MTHFD2 and uses thereof RAZE THERAPEUTICS, INC. (US) 2022-06-28 — — US disclosed
US-11370792-B2 Caffeine inhibitors of MTHFD2 and uses thereof RAZE THERAPEUTICS, INC. (US) 2022-06-28 — — US disclosed
US-20180370972-A1 CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF RAZE THERAPEUTICS, INC. 2018-12-27 — — US disclosed
EP-3389664-A1 CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF Raze Therapeutics Inc. (US) 2018-10-24 — — EP disclosed
WO-2017106352-A1 CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF RAZE THERAPEUTICS, INC. (US) 2017-06-22 — — WO disclosed
WO-2017106352-A1 CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF RAZE THERAPEUTICS, INC. (US) 2017-06-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12187728-B2 Caffeine inhibitors of MTHFD2 and uses thereof MTHFD2, MTHFD1, NUDT15 MAPT 1028/4885TP53 2424/4885USP2 1308/4885
US-11370792-B2 Caffeine inhibitors of MTHFD2 and uses thereof MTHFD2, MTHFD1, NUDT15 MAPT 1028/4885TP53 2424/4885USP2 1308/4885
US-20230067237-A1 CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF MTHFD2, MTHFD1, NUDT15 MAPT 1028/4885TP53 2424/4885USP2 1308/4885
US-20180370972-A1 CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF MTHFD2, MTHFD1, NUDT15 MAPT 1028/4885TP53 2424/4885USP2 1308/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback